Non-Invasive Prenatal Testing for Fetal Aneuploidy with Microdeletions
Ordering Recommendation

First- or second-tier screening test for the common fetal aneuploidy disorders: trisomy 13, trisomy 18, trisomy 21 (Down syndrome), Turner syndrome, sex chromosome aneuploidies (XXX, XXY, XYY), and triploidy; as well as microdeletions causing 22q11.2 deletion (DiGeorge or velocardiofacial [VCFS] syndrome), 1p36 deletion, Angelman, Prader-Willi, and cri-du-chat (5p-) syndromes. Testing may be offered to pregnant women from 9 weeks 0 days gestation to term. Test is not recommended for women who are carrying more than one fetus or have a known twin demise, patients who have used an egg donor, surrogates who have not used their own egg, or women who have had an allogenic bone marrow transplant.

Targeted Sequencing with SNPs
12-14 days
New York DOH Approval Status
This test is New York DOH approved.
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Whole blood in Cell-Free DNA BCT Tube. All specimens must be collected using the NIPT ANEU kit (ARUP Supply #50223) available online through eSupply or contacting ARUP Client Services at (800) 522-2787.
Required Specimen: Maternal specimens must be collected in 2 Cell-Free DNA BCT tubes. 
Specimen Preparation
Transport 20 mL maternal blood in Cell-Free DNA BCT Tube (ARUP Supply #50223) available online through eSupply or contacting ARUP Client Services at (800) 522-2787. (Min: 16 mL) 
Storage/Transport Temperature
Room temperature. 
Unacceptable Conditions
Patient History for Non-Invasive Prenatal Testing (NIPT) form required. 
Ambient: 5 days; Refrigerated: Unacceptable; Frozen: Unacceptable 
Reference Interval
By report
Interpretive Data
Refer to report.

Testing utilizes a single-nucleotide polymorphism (SNP)/informatics-based approach to detect fetal copy number for the five chromosomes responsible for the majority of live-birth aneuploidies (chromosomes 13, 18, 21, X, Y, and triploidy) and certain specific microdeletion syndromes (see current list of microdeletion syndromes listed under "Ordering Recommendations"). This is a screening test to help identify fetuses at risk for Down syndrome, trisomy 18, trisomy 13 and Turner syndrome, as well as fetuses affected with the specified microdeletion syndromes listed. This test should not be considered diagnostic. All positive results should be confirmed by amniocentesis or CVS.
Hotline History
Component Test Code*Component Chart NameLOINC
2008381Trisomy 2173966-4
2008382Trisomy 1873825-2
2008383Trisomy 1373824-5
2008386Monosomy X73821-1
2008430Fetal Fraction
2008431Report Fetal Sex?8251-1
2008830Triploidy/Vanishing Twin
2009259Result Summary48767-8
2009260Gestational Age at draw (Weeks)49051-6
2010002Maternal Weight (Pounds)8338-6
2010003Gestational Age at draw (Days)49052-4
2010004Fetal Sex11882-8
201035422q11.2 deletion syndrome
2010472Prader-Willi syndrome44617-9
2010473Cri-du-chat syndrome73751-0
2010474Angelman syndrome48024-4
2010475del 1p36 syndrome
2010646EER Fetal Aneuploidy w/Microdeletions
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • 45X
  • cell-free
  • cellfree
  • cffDNA
  • edward syndrome
  • Natera
  • NIPD
  • Panorama
  • patau syndrome
  • T13
  • T18
  • trisomy 21

Performed at Natera